Primary cardiac sarcoma: a novel treatment approach.
Primary cardiac sarcomas carry a dismal prognosis with no known curative therapy using standard treatment approaches. By its very location, the possibility of a radical complete resection--the underlying principle in the management of any soft-tissue sarcoma--is precluded. While literally in a continuous "blood bath," cardiac sarcomas are associated with a very high rate of hematogenous metastases. This report describes the management of a case in a 51-year-old white man with a high-grade unresectable cardiac sarcoma who was treated with hyperfractionated (twice daily) radiotherapy to a total dose of 7,050 cGy along with a radiosensitizer, (5'-iododeoxyuridine. The patient currently is disease-free and functioning well more than 5 years following this novel treatment approach.
Movsas
B
B
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Teruya-Feldstein
J
J
Smith
J
J
Glatstein
E
E
Epstein
A H
AH
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004452:Echocardiography; D005500:Follow-Up Studies; D006338:Heart Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018714:Radiotherapy, Adjuvant; D012509:Sarcoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents